Literature DB >> 20811974

The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions.

Yonat Keshet1, Rony Seger.   

Abstract

Sequential activation of kinases within the mitogen-activated protein (MAP) kinase (MAPK) cascades is a common, and evolutionary-conserved mechanism of signal transduction. Four MAPK cascades have been identified in the last 20 years and those are usually named according to the MAPK components that are the central building blocks of each of the cascades. These are the extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-Terminal kinase (JNK), p38, and ERK5 cascades. Each of these cascades consists of a core module of three tiers of protein kinases termed MAPK, MAPKK, and MAP3K, and often two additional tiers, the upstream MAP4K and the downstream MAPKAPK, which can complete five tiers of each cascade in certain cell lines or stimulations. The transmission of the signal via each cascade is mediated by sequential phosphorylation and activation of the components in the sequential tiers. These cascades cooperate in transmitting various extracellular signals and thus control a large number of distinct and even opposing cellular processes such as proliferation, differentiation, survival, development, stress response, and apoptosis. One way by which the specificity of each cascade is regulated is through the existence of several distinct components in each tier of the different cascades. About 70 genes, which are each translated to several alternatively spliced isoforms, encode the entire MAPK system, and allow the wide array of cascade's functions. These components, their regulation, as well as their involvement together with other mechanisms in the determination of signaling specificity by the MAPK cascade is described in this review. Mis-regulation of the MAPKs signals usually leads to diseases such as cancer and diabetes; therefore, studying the mechanisms of specificity-determination may lead to better understanding of these signaling-related diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811974     DOI: 10.1007/978-1-60761-795-2_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  213 in total

1.  Enzyme-sharing as a cause of multi-stationarity in signalling systems.

Authors:  Elisenda Feliu; Carsten Wiuf
Journal:  J R Soc Interface       Date:  2011-11-02       Impact factor: 4.118

2.  Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.

Authors:  Natalie B Vinh; Jamie S Simpson; Peter J Scammells; David K Chalmers
Journal:  J Comput Aided Mol Des       Date:  2012-04-20       Impact factor: 3.686

3.  Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidant injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of Bcl-2.

Authors:  A Sanchez; D Tripathy; X Yin; J Luo; J Martinez; P Grammas
Journal:  Neurosci Res       Date:  2011-09-17       Impact factor: 3.304

4.  An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation.

Authors:  Cemile G Guldal; Adiba Ahmad; Andrey Korshunov; Massimo Squatrito; Aashir Awan; Lori A Mainwaring; Bipin Bhatia; Susana R Parathath; Zaher Nahle; Stefan Pfister; Anna M Kenney
Journal:  Acta Neuropathol       Date:  2012-04       Impact factor: 17.088

5.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

6.  Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1/2.

Authors:  Veronika Reiterer; Dirk Fey; Walter Kolch; Boris N Kholodenko; Hesso Farhan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-11       Impact factor: 11.205

7.  Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.

Authors:  Elizabeth A Sabens Liedhegner; Kelly M Steller; John J Mieyal
Journal:  Chem Res Toxicol       Date:  2011-08-22       Impact factor: 3.739

8.  MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

Authors:  Sobhana Babu Boga; Yongqi Deng; Liang Zhu; Yang Nan; Alan B Cooper; Gerald W Shipps; Ronald Doll; Neng-Yang Shih; Hugh Zhu; Robert Sun; Tong Wang; Sunil Paliwal; Hon-Chung Tsui; Xiaolei Gao; Xin Yao; Jagdish Desai; James Wang; Abdul Basit Alhassan; Joseph Kelly; Mehul Patel; Kiran Muppalla; Subrahmanyam Gudipati; Li-Kang Zhang; Alexei Buevich; David Hesk; Donna Carr; Priya Dayananth; Stuart Black; Hong Mei; Kathleen Cox; Bradley Sherborne; Alan W Hruza; Li Xiao; Weihong Jin; Brian Long; Gongjie Liu; Stacey A Taylor; Paul Kirschmeier; William T Windsor; Robert Bishop; Ahmed A Samatar
Journal:  ACS Med Chem Lett       Date:  2018-06-14       Impact factor: 4.345

9.  Beta-like importins mediate the nuclear translocation of mitogen-activated protein kinases.

Authors:  Eldar Zehorai; Rony Seger
Journal:  Mol Cell Biol       Date:  2013-11-11       Impact factor: 4.272

10.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.